Diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion. Close resemblance of its clinicopathological features to intravascular large B-cell lymphoma, but not to DLBCL-not otherwise specified
| Autor: | Tomomi Fujii, Yuji Nitta, Hirokazu Nakamine, Tomoko Uchiyama, Chiho Ohbayashi, Shinji Nakamura, Masayuki Kubo, Kinta Hatakeyama, Hiroe Itami, Maiko Takeda, Kohei Ogawa, Rina Tani |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
PD-L1
Pathology medicine.medical_specialty Diagnosis Differential immune system diseases hemic and lymphatic diseases medicine Humans Neoplasm Invasiveness Neoplasm Metastasis neoplasms Neoplasm Staging Intravascular large B-cell lymphoma biology business.industry Not Otherwise Specified Diffuse large B-cell lymphoma General Medicine medicine.disease Intravascular lymphoma Lymphoma Splenomegaly biology.protein Blood Vessels Immunohistochemistry Original Article Lymphoma Large B-Cell Diffuse CD5 Hemophagocytosis business |
| Zdroj: | Journal of Clinical and Experimental Hematopathology : JCEH |
| ISSN: | 1880-9952 1346-4280 |
| DOI: | 10.3960/jslrt.20066 |
| Popis: | Intravascular large B-cell lymphoma (IVLBCL) is defined by the World Health Organization (WHO) Classification as one type of extranodal large B-cell lymphoma and it is characterized by the selective growth of lymphoma cells within blood vessels with minimal extravascular invasion. According to the criteria, however, several reported cases of IVLBCL with significant extravascular invasion cannot be classified as IVLBCL. The purpose of the present study was to assess the clinicopathological significance of the WHO criteria for IVLBCL. We characterized clinical, histopathological, and immunohistochemical features of 11 patients with extranodal diffuse large B-cell lymphoma (DLBCL) with significant intravascular invasion (DLBCL-IV), and statistically compared their features with those of 11 patients with IVLBCL and 15 patients with extranodal DLBCL with virtually no intravascular invasion (DLBCL-noIV). When compared with the DLBCL-noIV group, the DLBCL-IV group was characterized by significantly higher rates of splenomegaly, hemophagocytosis, advanced stage disease, and CD5 expression; higher average platelet count, serum lactate dehydrogenase level, and serum ferritin level. Progression-free survival was significantly shorter in the DLBCL-IV group than the DLBCL-noIV group. In contrast, there were no significant differences in clinicopathological features between the DLBCL-IV and the IVLBCL groups. Our study suggests that DLBCL-IV should be regarded as IVLBCL-related. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|